Raymond James Financial Inc. purchased a new position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 101,346 shares of the biopharmaceutical company's stock, valued at approximately $2,329,000. Raymond James Financial Inc. owned approximately 0.14% of Xencor at the end of the most recent reporting period.
Several other institutional investors have also made changes to their positions in the company. Arizona State Retirement System raised its position in Xencor by 13.3% during the fourth quarter. Arizona State Retirement System now owns 18,190 shares of the biopharmaceutical company's stock valued at $418,000 after acquiring an additional 2,132 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Xencor by 0.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 630,640 shares of the biopharmaceutical company's stock worth $14,492,000 after purchasing an additional 3,652 shares during the last quarter. Mutual of America Capital Management LLC bought a new position in shares of Xencor during the 4th quarter valued at $244,000. Oregon Public Employees Retirement Fund lifted its stake in shares of Xencor by 13.8% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 16,512 shares of the biopharmaceutical company's stock valued at $379,000 after purchasing an additional 2,000 shares during the last quarter. Finally, Illinois Municipal Retirement Fund boosted its holdings in Xencor by 25.8% in the fourth quarter. Illinois Municipal Retirement Fund now owns 33,198 shares of the biopharmaceutical company's stock worth $763,000 after purchasing an additional 6,802 shares in the last quarter.
Wall Street Analysts Forecast Growth
A number of brokerages have weighed in on XNCR. Piper Sandler raised Xencor from a "neutral" rating to an "overweight" rating and boosted their price target for the stock from $20.00 to $30.00 in a research report on Monday, December 2nd. StockNews.com lowered Xencor from a "hold" rating to a "sell" rating in a report on Friday, March 14th. Finally, Wells Fargo & Company decreased their target price on Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Xencor currently has a consensus rating of "Moderate Buy" and a consensus target price of $34.38.
Check Out Our Latest Report on Xencor
Xencor Stock Performance
XNCR stock traded down $0.58 on Tuesday, reaching $10.07. 325,866 shares of the company were exchanged, compared to its average volume of 595,504. The firm has a market capitalization of $709.20 million, a PE ratio of -3.16 and a beta of 0.74. Xencor, Inc. has a 12 month low of $10.06 and a 12 month high of $27.24. The stock's fifty day moving average price is $15.39 and its 200 day moving average price is $20.01. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23.
Xencor (NASDAQ:XNCR - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The company had revenue of $52.79 million for the quarter, compared to the consensus estimate of $17.14 million. On average, research analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current fiscal year.
About Xencor
(
Free Report)
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Read More
Before you consider Xencor, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xencor wasn't on the list.
While Xencor currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
